Scynexis, Inc. is a biotechnology company, which focuses on the treatment of fungal infections.



Toggle Chart Options

Range Dropdown

$ % Vol

Volume: 52.89M Avg. 65-Day: 1.2M

4,414% vs Average 2.4200 Day range 2.9700 1.1500 Week Range 4.0400

Key Data

% of Float Shorted 2.49
Average Volume 1.2M

The Performance of a

5 Day


One Month


Three Months


Year to Date


One Year


Analyst Ratings


Number of ratings 2 Full Ratings

MarketWatch Dow Jones

Health Care: Higher Inflation Hedging in Health Care Roundup

30th, 2023 at 4:11 p.m. ET

30.2023 at 3:46 pm. ET by Tomi Ilgore

Scynexis shares jump 60% after GSK licensing deal

30th, 2023 10:13 am ET

Biotech and Pharma Antifungal Maker Scynexis Stock soars after GSK Deal

30th, 2023 at 9 a.m. Barron's

Healthcare CDC Alarms About Deadly Fungus Six Things You Should Know.

22.2023 at 9:25 am. Barron's

Scynexis' stock price target is reduced to $15.00, from $22.50 by Ladenburg Thalmann

13th, 2022 7:53 am ET by Tomi Ilgore

Maxim Group has reduced the price target for Scynexis to $16 per share from $22

Nov. 17, 2020 at 8:50 am ET by Tomi Ilgore

Maxim Group has raised the price target for Scynexis to $22 from $17.

17th February 2021, 11:51 am ET by Tomi KILGORE

Maxim Group has reduced the price target for Scynexis to $15, down from $40.

21.2020 at 9:25 am. Tomi Kilgore

RBC: Some cheap biotech stocks could be bought out by investors

25 January 2016 at 1:31 pm Emma Court

Press Releases on Other News

Dow rises 100 points; Accelerate Diagnostics shares soar higher

30th, 2023 at 2 p.m. ET on

Twelve Health Care Stocks Moved In Intraday Trading On Thursday

30th, 2023 at 12:31 pm ET on ET on

Why Bed Bath & Beyond Stocks are Trading Lower by 15%? What Other Stocks Moved In The Midday Session On Thursday?

30th, 2023 12:43 PM ET on ET on

Analysts offer insights on healthcare companies: Xoma and SCYNEXIS

30th, 2023 at 11 a.m.

GSK Bets on Scynexis FDA-approved antifungal drug for over $500M in Bio Bucks

30th, 2023 at 11 a.m. ET on

Warner Music layoffs: What you need to know about the latest job cuts

30th, 2023 at 10 a.m.

Why is Scynexis stock up 69% today?

30th, 2023 10:26 am ET on

Twelve Health Care Stocks Moved In Wednesday's intraday session

1 at 12:31 pm ET on ET on

Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023

The 10 biggest stock gainers and losers of Monday's pre-market:

Dec. 30, 2020 at 12:02 pm. ET on

Stocks that hit 52-week lows on Wednesday

Dec. 28, 2020 at 11:23 am ET on ET on

SCYNEXIS Return on Capital Employed Overview


SCYNEXIS, Inc., is a biotechnology firm that develops novel triterpenoid oral and intravenous antifungals for the treatment invasive fungal infection, such as vulvovaginal Candida, invasive Aspergillosis, or invasive Candidiasis. The company was founded on November 4, 1998 by Scot Kevin Huber and Terry Eugene Marquardt. Its headquarters are in Jersey City, NJ.